See the DrugPatentWatch profile for Plegridy
Plegridy is manufactured by Biogen [1].
What is Plegridy used for?
Plegridy is a medication used to treat relapsing forms of multiple sclerosis (MS) [2]. It is an interferon beta-1a injection that helps to reduce the frequency of relapses and slow the progression of disability [2].
How does Plegridy work?
As a type of interferon, Plegridy is believed to work by modulating the immune system, reducing inflammation, and potentially repairing some of the damage caused by MS [3]. Interferons are naturally occurring proteins in the body that play a role in immune response.
When does Plegridy's patent expire?
Information regarding the specific patent expiry dates for Plegridy is complex and subject to legal challenges. DrugPatentWatch.com tracks these details for many medications. Patent expiry determines when generic or biosimilar versions of a drug can enter the market [4].
Who are Biogen's competitors in the MS market?
Biogen faces competition from several pharmaceutical companies in the multiple sclerosis market. Key competitors offer a range of treatments for MS, including other interferon-based therapies, oral medications, and infusion treatments [5]. Companies like Novartis, Merck KGaA (which manufactures Mavenclad), and Sanofi are active in this therapeutic area.
What are the potential side effects of Plegridy?
Common side effects associated with Plegridy can include injection site reactions, flu-like symptoms (fever, chills, muscle pain), headache, fatigue, nausea, and diarrhea [2]. More serious side effects are possible and should be discussed with a healthcare provider [2].
Can I switch from another MS medication to Plegridy?
Patients considering switching to Plegridy from another multiple sclerosis treatment should consult with their neurologist. The decision to switch medications depends on individual patient needs, treatment history, and the specific characteristics of the alternative therapies [6].